Study Detail

Study of the safety of & response to a COVID-19 vaccine in pregnancy

A Randomised, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants

Status: Withdrawn

Type: Interventional

Funder: Janssen-Cilag Ltd

Sponsor: Janssen-Cilag Ltd

CI: Prof Chloe Orkin

IRAS-Number: 293579

CPMS-ID: 47953

Approval Date: 17 February 2021

Back to listing